ClinicalTrials.Veeva

Menu

Liposomal Based Intranasal Influenza Vaccine:Safety and Efficacy

H

Hadassah Medical Center

Status and phase

Completed
Phase 2
Phase 1

Conditions

Influenza

Treatments

Biological: Vaccination

Study type

Interventional

Funder types

Other

Identifiers

NCT00197301
16-05.08.05-HMO-CTIL

Details and patient eligibility

About

Influnza vaccination is highly recommended over the age of 50,but is only 50% efficatious among the elderly. A Vaccine given as a nasal spray may improve compliance and local immunity.Liposomes are lipid particles that may serve as carriers for the vaccine and together they enhance the local immune response in mice when given as nasal spray.This study aims to examine the safety and nasal and humoral responses to the nasal vaccine compared to the commercial muscular vaccine.

Sex

All

Ages

20 to 95 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Healthy young(20-45years old) and elderly(65-95 years old) volunteers -

Exclusion Criteria:Known allergy to eggs and to the flu vaccine, pregnant and breast feeding women, chronic viral carriers, recently hospitalized persons

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems